Abstract: The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.

Abstract: The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.

Abstract: The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The invention provides methods for improving at least one physicochemical property of a product comprising casein micelles, the method comprising applying carbon dioxide to an aqueous product comprising casein micelles to reduce the pH of the product; increasing the pH of the product; and collecting the product comprising casein micelles, in which at least some of the casein micelles of the product are modified in structure by one or more of steps a) and b) compared to naturally occurring casein micelles thereby improving at least one physicochemical property of the product comprising casein micelles. The method reduces viscosity and improves mouth feel of reconstituted product, reduces rehydration time for dried product, improves cheese manufacturing by reducing rennetting or clotting time in cheese manufacture or reducing the amount of rennet required in cheese manufacture.

Abstract: The invention provides a method for treating cachexia, weakness, fatigue, and/or fever in a subject, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist. The method is particularly applicable to the prevention or treatment of cancer cachexia.

Abstract: The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.

Abstract: The invention provides a process for the preparation of an angiogenin-enriched fraction from a milk product, the process comprising contacting the milk product with a cation exchange resin and eluting the angiogenin-enriched fraction from the cation exchange resin with a mobile phase. The invention also provides angiogenin-enriched fractions produced by process and food products, nutraceuticals and pharmaceutical comprising such angiogenin.

Abstract: The method relates to a method of treating proteinuria comprising administering lactoferrin.

Abstract: The invention provides a non-human transgenic animal comprising a transgene encoding angiogenin and food products comprising or obtained from the non-human transgenic animal and uses thereof.

Abstract: The invention relates to the production of compositions containing IgA for use as a food additive. More specifically, it relates to a process to prepare an IgA-enriched milk product extract composition and to such compositions.

Abstract: The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or for the protein to be encapsulated or subjected to any other mechanism to improve its oral bioavailability.

Abstract: The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuro-protection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.

Abstract: The invention provides a process for the preparation of an angiogenin-enriched fraction from a milk product, the process comprising contacting the milk product with a cation exchange resin and eluting the angiogenin-enriched fraction from the cation exchange resin with a mobile phase. The invention also provides angiogenin-enriched fractions produced by process and food products, neutraceuticals and pharmaceutical comprising such angiogenin.

Abstract: The invention relates to the production of compositions containing IgA for use as a food additive. More specifically, it relates to a process to prepare an IgA-enriched milk product extract composition and to such compositions.

Abstract: The present invention provides a process for validating the efficacy of a sample having a known activity determined using a biological assay. The process includes subjecting the sample to a biological assay capable of testing for the activity. The process may optionally include an initial step of determining a biological assay for the desired activity. The present invention is particularly applicable to samples from milk.